Ann: Oncosil breakthrough device receives CE Marking approval, page-145

cast aspersions if you wish, it’s of no concern. The fact remains this company has much catching up to do and needs to communicate a convincing and coherent commercial and R&D plan . If an October launch from the Dr Boreham biotech daily piece is accurate, then market research should be well advanced to gauge acceptance by oncologists in the target markets of a small uncontrolled pilot study . Reimbursement is stated by the CEO as being “widely available” in the same report - what is the basis for that belief and what has iqvia’s reimbursement work revealed? It took Celgene 3-4 years of struggle to get abraxane reimbursed by NICE in UK for PC, and they had higher level evidence to offer than OSL ( an 860 patient proper randomised control trial confirming a survival advantage over standard of care). Again , what are the proposed follow up clinical plans. When will the final Panco trial results be published. We all look forward to forthcoming announcements.